Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus
- PMID: 32086501
- DOI: 10.1038/s41579-020-0331-1
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus
Abstract
Infections caused by non-tuberculous mycobacteria (NTM) are increasing globally and are notoriously difficult to treat due to intrinsic resistance of these bacteria to many common antibiotics. NTM are diverse and ubiquitous in the environment, with only a few species causing serious and often opportunistic infections in humans, including Mycobacterium abscessus. This rapidly growing mycobacterium is one of the most commonly identified NTM species responsible for severe respiratory, skin and mucosal infections in humans. It is often regarded as one of the most antibiotic-resistant mycobacteria, leaving us with few therapeutic options. In this Review, we cover the proposed infection process of M. abscessus, its virulence factors and host interactions and highlight the commonalities and differences of M. abscessus with other NTM species. Finally, we discuss drug resistance mechanisms and future therapeutic options. Taken together, this knowledge is essential to further our understanding of this overlooked and neglected global threat.
Similar articles
-
Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e01146-17. doi: 10.1128/AAC.01146-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28739795 Free PMC article.
-
Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.Infect Genet Evol. 2019 Aug;72:169-182. doi: 10.1016/j.meegid.2018.10.003. Epub 2018 Oct 11. Infect Genet Evol. 2019. PMID: 30315892 Review.
-
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01105-18. doi: 10.1128/AAC.01105-18. Print 2018 Oct. Antimicrob Agents Chemother. 2018. PMID: 30104265 Free PMC article.
-
The treatment of rapidly growing mycobacterial infections.Clin Chest Med. 2015 Mar;36(1):67-78. doi: 10.1016/j.ccm.2014.10.004. Epub 2014 Nov 5. Clin Chest Med. 2015. PMID: 25676520 Review.
-
In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus.Microbiol Spectr. 2022 Feb 23;10(1):e0132121. doi: 10.1128/spectrum.01321-21. Epub 2022 Jan 12. Microbiol Spectr. 2022. PMID: 35019671 Free PMC article.
Cited by
-
Beauty's Betrayal: Mycobacterium abscessus Case Series Following Aesthetic Procedures in the Brazilian Amazon.Infect Dis Rep. 2024 Aug 7;16(4):724-734. doi: 10.3390/idr16040055. Infect Dis Rep. 2024. PMID: 39195006 Free PMC article.
-
Identification Mycobacterium spp. in the Natural Water of Two Austrian Rivers.Microorganisms. 2020 Aug 27;8(9):1305. doi: 10.3390/microorganisms8091305. Microorganisms. 2020. PMID: 32867056 Free PMC article.
-
Efficacy and Mechanisms of Flavonoids against the Emerging Opportunistic Nontuberculous Mycobacteria.Antibiotics (Basel). 2020 Jul 27;9(8):450. doi: 10.3390/antibiotics9080450. Antibiotics (Basel). 2020. PMID: 32726972 Free PMC article. Review.
-
Prevalence of resistance to macrolides and aminoglycosides in Mycobacterium avium, M. abscessus, and M. chelonae identified in the Laboratorio Nacional de Referencia of Colombia from 2018 to 2022.Biomedica. 2024 May 30;44(2):182-190. doi: 10.7705/biomedica.7197. Biomedica. 2024. PMID: 39088528 Free PMC article. English, Spanish.
-
Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline.PLoS Pathog. 2021 Oct 12;17(10):e1009965. doi: 10.1371/journal.ppat.1009965. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34637487 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical